Hepatitis C Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Rise in Prevalence of Hepatitis C
   3. Market Restraints
      1. High Cost of Treatment
      2. Stigma and Awareness
   4. Market Opportunities
      1. Launch of New Products
   5. Market Trends
      1. Increased Focus on Elimination Efforts
      2. Adoption of Novel Therapeutic Approaches
5. MARKET SEGMENTATION
   1. By Type
      1. Acute Hepatitis C
      2. Chronic Hepatitis C
      3. Other
   2. By Treatment
      1. Antiviral Drugs
      2. Telbivudine
      3. Entecavir
      4. Tenofovir disoproxil
      5. Lamivudine
      6. Others
      7. Vaccine
      8. Immune Modulator Drugs
      9. Pegylated interferon
      10. Interferon alpha
      11. Surgery
      12. Others
   3. By Diagnosis
      1. Liver Biopsy
      2. Blood Tests
      3. Imaging Tests
      4. Ultrasound
      5. MRI
      6. CT scan
      7. Others
   4. By Route of Administration
      1. Oral
      2. Parenteral
      3. Others
   5. By End-Users
      1. Hospitals
      2. Specialty Clinics
      3. Homecare
      4. Others
   6. By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
      4. Others
2. By Key Geographic Regions
   1. North America
      1. United States
      2. Canada
      3. Mexico
   2. Europe
      1. Germany
      2. United Kingdom
      3. France
      4. Italy
      5. Spain
      6. Rest of Europe
   3. Asia Pacific
      1. China
      2. Japan
      3. India
      4. Australia
      5. South Korea
      6. Rest of Asia Pacific
   4. Middle East and Africa
      1. GCC
      2. South Africa
      3. Rest of Middle East and Africa
   5. South America
      1. Brazil
      2. Argentina
      3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Aurobindo Pharma (India)
      2. AstraZeneca (U.K.)
      3. Boehringer Ingelheim International GmbH. (Germany)
      4. Bristol-Myers Squibb Company (U.S.)
      5. Bayer AG (Germany)
      6. Cipla Inc. (U.S.)
      7. Cadila Pharmaceuticals (India)
      8. Eli Lilly and Company (U.S.)
      9. F. Hoffmann-La Roche Ltd. (Switzerland)
      10. GlaxoSmithKline plc (U.K.)
      11. Johnson & Johnson Private Limited (U.S.)
      12. LEO Pharma A/S (Denmark)
      13. Lupin (India)
      14. Merck & Co., Inc. (U.S.)
      15. Mylan N.V. (U.S.)
      16. Novartis AG (Switzerland)
      17. Pfizer Inc. (U.S.)
      18. Sanofi (France)
      19. Sumitomo Corporation (Japan)
      20. Teva Pharmaceutical Industries Ltd. (Israel)

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Hepatitis Cmarket?

The global market of Hepatitis C is projected to reach USD 224.06 Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Hepatitis Cmarket?

The global Hepatitis C market has an estimated annual growth rate of 13.6% .

Q.3. What are the recent trends of Hepatitis Cmarket?

Increased focus on elimination efforts and adoption of novel therapeutic approaches are some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Hepatitis C?

The major companies profiled in this report include Aurobindo Pharma (India), AstraZeneca (U.K.), Boehringer Ingelheim International GmbH. (Germany), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), Cipla Inc. (U.S.), Cadila Pharmaceuticals (India), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc (U.K.), Johnson & Johnson Private Limited (U.S.), LEO Pharma A/S (Denmark), Lupin (India), Merck & Co., Inc. (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Sanofi (France), Sumitomo Corporation (Japan), Teva Pharmaceutical Industries Ltd. (Israel), among others.

Q.5. Which region is estimated to held highest CAGR inHepatitis Cmarket?

North America is estimated to hold biggest share in the market for Hepatitis C.